inactivation of aromatase in human placenta and uterine leiomyoma by 5\g=a\-dihydronorethindrone,a metabolite of norethindrone, and its effect on steroid-producing enzymes. Eur J Endocrinol 1994;130:634\p=n-\40,ISSN 0804\p=n-\4643 Norethindrone (NET; 1 7 \ g = a \ -e t h y n y l -1 9 -n o r t e s t o s t e r o n e ) , 
tive pill, irreversibly inhibits aromatase activity in human placental microsomes. However, it is known also to be aromatized in vitro and in vivo to produce a biologically very active estrogen called ethynylestradiol (EE2). It is therefore inappropriate to administer a high dose of NET to estrogendependent cancer patients for a prolonged time period. In this study, we focused on 5 \ g = a \ -d i h y d r o n o rethindrone (5\g=a\-DHNET),a metabolite of NET that is not aromatizable, and the inhibitory effects of 5\ g=a\ \ x=r eq-\ DHNET on human placental and uterine leiomyoma microsomal aromatase and other steroid synthetases. 5\g=a\-Dihydronorethindrone showed weak affinity for both estrogen and progestogen receptors. It inhibited significantly human placental aromatase activity in a dose-dependent manner (Ki = 9.0 \g=m\mol/l; Kinact = 0.024/min), as well as that of uterine leiomyoma, but did not influence cholesterol side-chain cleavage or 17\g=a\-hydroxylase,21-hydroxylase or 11\g=b\-hydroxylase activities. These results suggest that 5 in Japan has shown a tendency to increase in recent years. The development of breast cancer (1) and uterine endometrial cancer (2) generally is known to be related closely to estrogen activity. (4) . We confirmed the fact that NET irreversibly inactivates human placental aromatase. However, it was later revealed that human adult liver (5, 6) [4-14C] androstenedione (52.0 mCi/mmol), [7-3H] cholesterol (11.4 Ci/mmol) and [4-14C] (Fig. 3) preincubation time and was dependent on the 5a-DHNET concentration (Fig. 4) . Preincubation of human placental microsomes with 5a-DHNET and NADPH showed significantly greater inhibition of aromatase activity than preincubation without NADPH. The results show that 5a-DHNET irreversibly inactivates human placental aromatase. The K, and Kinact values of 5a-DHNET were 9.0 //mol/1 and 0.024/min, respectively, indicating a mild inhibitory effect.
The inhibitory effect of 5a-DHNET on aromatase activity in human uterine leiomyoma
As shown in Fig. 5 , the aromatase activity of the microsomal fraction of uterine leiomyoma was inhibited dose dependently by the addition of 5a-DHNET (up to 80 µ / ).
The effect of 5a-DHNET on the activity of other steroid synthetases
The formation of progesterone was reduced following the addition of trilostane, but the total sum of the formation of pregnenolone and progesterone was not altered, indicating that trilostane did not affect CSCC activity. As shown in Fig. 6A , the CSCC enzyme activity of bovine adrenocortical mitochondria was not inhibited by the addition of 5a-DHNET (up to 160 µ / ). The 11/3-hydroxyIase activity of bovine adrenocortical mitochondria was only inhibited slightly by the addition of 5a-DHNET (up to 300 µ / ) (Fig. 6B) .
The 21-hydroxylase activity of bovine adrenocortical microsomes was enhanced by about 20% by low concentrations (0-40 µ / ) of 5a-DHNET but was not influenced by higher concentrations µ / ) of 5a-DHNET (Fig. 7A) .
The 17a-hydroxylase activity of bovine adrenocortical microsomes was not affected by low concentrations (0-40 µ / ) of 5a-DHNET but was inhibited dose dependently to some degree (20-40%) by more than 80 µ / 5a-DHNET (Fig. 7B) .
The results show that 5a-DHNET slightly inhibits 17a-hydroxylase in higher concentrations but does not affect the activity of CSCC enzyme, 11/3-hydroxylase or 21-hydroxylase. 
